je.st
news
Home
› La Jolla Pharmaceutical Announces Positive Pre-Clinical Data For Oral Galectin-3 Inhibitor In Nonalcoholic Steatohepatitis (NASH)
La Jolla Pharmaceutical Announces Positive Pre-Clinical Data For Oral Galectin-3 Inhibitor In Nonalcoholic Steatohepatitis (NASH)
2014-07-30 09:57:01| drugdiscoveryonline Home Page
La Jolla Pharmaceutical Company (the “Company” or “La Jolla”), a leader in the development of therapeutics targeting significant unmet life-threatening diseases,recently announced positive pre-clinical data for LJPC-1010 in non-alcoholic steatohepatitis (NASH). LJPC-1010 is a derivative of GCS-100, a carbohydrate inhibitor of galectin-3, which has shown activity in chronic kidney disease in a Phase 2 trial
Tags: data
positive
oral
pharmaceutical
Category:Biotechnology and Pharmaceuticals